Table 2.
Treatment | Proportion of Patients on Intervention in Base Case (%) |
---|---|
Rituximab | 68.2% |
Bendamustine | 57.4% |
Bortezomib | 5.5% |
Anthracycline-based | 7.3% |
Total | 138.5% |
Note: Sum is more than 100% as patients can be given these drugs in combination.